source
- STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.STAT · 2mo ago↗ source
- STAT+: Hims’ sales miss as telehealth competition growsBristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The ReadoutSTAT · 2mo ago↗ source
- Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drugA deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.BioPharma Dive · 2mo ago↗ source